

RANG & DALE'S

Pharmacology

TENTH EDITION

JAMES M. RITTER

DPHil FRCP HonFBPhS FMedSci

Emeritus Professor of Clinical Pharmacology
King's College London
London, United Kingdom

ROD FLOWER

PhD LLD DSc HonFBPhS FMedSci FRS

Emeritus Professor of Pharmacology
Bart's and the London School of Medicine
Queen Mary, University of London
London, United Kingdom

GRAEME HENDERSON

PhD, FRSB, HonFBPhS

Professor of Pharmacology
University of Bristol
Bristol, United Kingdom

YOON KONG LOKE

MBBS MD FRCP FBPhS

Professor of Medicine and Pharmacology
Norwich Medical School, University of East Anglia
Norwich, United Kingdom

DAVID MacEWAN

PhD FRSB FBPhS SFHEA

Professor of Molecular Pharmacology/Toxicology
Deputy Executive Dean
University of Liverpool
Liverpool, United Kingdom

EMMA ROBINSON

PhD FBPhS

Professor of Psychopharmacology
University of Bristol
Bristol, United Kingdom

JAMES FULLERTON

MA MBChB MRCP PhD FHEA

Associate Professor of Clinical Therapeutics
University of Oxford
Consultant in Acute General Medicine and Clinical
Pharmacology
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Visit Elsevier eBooks+ (eBooks.Health.Elsevier.com) for additional online content



ELSEVIER

London New York Oxford Philadelphia St Louis Sydney 2024



SECTION 1 General principles

1 What is pharmacology? 1

- What is a drug? 1
- Origins and antecedents 1
- Pharmacology in the 20th and 21st centuries 2
 - Alternative therapeutic principles 3
 - The emergence of biotechnology 4
 - Pharmacology today 4

2 How drugs act: general principles 6

- Introduction 6
- Protein targets for drug binding 6
 - Drug receptors 6
 - Drug specificity 7
 - Receptor classification 8
 - Drug–receptor interactions 8
 - Competitive antagonism 11
 - Partial agonists and the concept of efficacy 12
 - Constitutive receptor activation and inverse agonists 14
 - Biased agonism 16
 - Allosteric modulation 17
 - Other forms of drug antagonism 17
- Desensitisation and tolerance 19
 - Change in receptors 19
 - Translocation of receptors 19
 - Exhaustion of mediators 20
 - Altered drug metabolism 20
 - Physiological adaptation 20
- Quantitative aspects of drug–receptor interactions 20
 - The binding reaction 20
 - Binding when more than one drug is present 21
- The nature of drug effects 22

3 How drugs act: molecular aspects 24

- Protein targets for drug action 24
 - Receptors 24
 - Ion channels 24
 - Enzymes 25
 - Transporters 25
- Receptor proteins 26
 - Types of receptor 26
 - Molecular structure of receptors 26
 - Type 1: ligand-gated ion channels 28
 - Type 2: G protein-coupled receptors 30
 - Type 3: kinase-linked and related receptors 42
 - Type 4: nuclear receptors 44
- Ion channels as drug targets 47
 - Ion selectivity 49
 - Gating 49
 - Molecular architecture of ion channels 49
 - Pharmacology of ion channels 50

- Control of receptor expression 51
- Receptors and disease 51

4 How drugs act: cellular aspects – excitation, contraction and secretion 54

- Regulation of intracellular calcium 54
 - Calcium entry mechanisms 54
 - Calcium extrusion mechanisms 57
 - Calcium release mechanisms 57
 - Calmodulin 58
- Excitation 58
 - The ‘resting’ cell 59
 - Electrical and ionic events underlying the action potential 59
 - Channel function 60
- Muscle contraction 65
 - Skeletal muscle 65
 - Cardiac muscle 65
 - Smooth muscle 65
- Release of chemical mediators 67
 - Exocytosis 68
 - Non-vesicular release mechanisms 69
- Epithelial ion transport 69

5 How drugs act: biopharmaceuticals and gene therapy 72

- Introduction 72
- Protein and peptide biopharmaceuticals 72
 - Monoclonal antibodies 74
 - Pharmacology of protein biopharmaceuticals 75
- Oligonucleotides 77
 - RNA drugs that target proteins 77
 - RNA drugs that target other nucleotides 79
 - RNA drugs that are used to encode proteins 79
 - Miscellaneous other RNA species with pharmacological potential 80
 - Problems with RNA biopharmaceuticals 80
- Gene therapy 81
 - Gene delivery 82
 - Controlling gene expression 84
- Safety and societal issues 84
- Therapeutic applications 85
- Future directions 85

6 Cell proliferation, apoptosis, repair and regeneration 87

- Cell proliferation 87
 - The cell cycle 87
 - Interactions between cells, growth factors and the extracellular matrix 90
- Angiogenesis 91
- Apoptosis and cell removal 91
 - Morphological changes in apoptosis 92
 - The major players in apoptosis 92
 - Pathways to apoptosis 92

- Pathophysiological implications 94
 - Repair and healing 94
 - Hyperplasia 95
 - The growth, invasion and metastasis of tumours 95
 - Stem cells and regeneration 95
- Therapeutic prospects 95
 - Apoptotic mechanisms 96
 - Angiogenesis and metalloproteinases 96
 - Cell cycle regulation 96

7 Cellular mechanisms: host defence 98

- Introduction 98
- The innate immune response 98
 - Pattern recognition 99
- The adaptive immune response 104
 - The induction phase 105
 - The effector phase 106
- Systemic responses in inflammation 109
 - The role of the nervous system in inflammation 109
 - Unwanted inflammatory and immune responses and their unintended consequences 109
 - The outcome of the inflammatory response 110

8 Method and measurement in pharmacology 112

- Bioassay 112
 - Biological test systems 112
 - General principles of bioassay 114
- Animal models of disease 116
 - Pharmacological models 116
 - Genetically altered animal models 116
 - Reducing use of animals in research 117
- Pharmacological studies in humans 118
- Clinical trials 118
 - Risk of bias in randomised controlled trials 119
 - The size of the sample 120
 - Clinical outcome measures 120
 - Placebos 120
 - Meta-analysis 121
 - Clinical consideration of benefit and risk 121

9 Absorption and distribution of drugs 123

- Introduction 123
- Physical processes underlying drug disposition 123
 - The movement of drug molecules across cell barriers 123
 - Binding of drugs to plasma proteins 129
 - Partition into body fat and other tissues 130
- Drug absorption and routes of administration 130
 - Oral administration 131
 - Oromucosal (sublingual or buccal) administration 133
 - Rectal administration 133
 - Application to epithelial surfaces 133
 - Intravitreal injection 134
- Distribution of drugs in the body 135
 - Body fluid compartments 135
 - Volume of distribution 136
 - Drug interactions caused by altered absorption 137

- Drug interactions caused by altered distribution 137
- Special drug delivery systems 137

10 Drug metabolism and elimination 140

- Introduction 140
 - Drug metabolism 140
 - Phase 1 reactions 140
 - Phase 2 reactions 142
 - Stereoselectivity 142
 - Inhibition of P450 143
 - Induction of microsomal enzymes 143
 - Presystemic ('first-pass') metabolism 143
 - Pharmacologically active drug metabolites 144
 - Drug interactions due to enzyme induction or inhibition 144
- Drug and metabolite excretion 146
 - Biliary excretion and enterohepatic circulation 146
 - Renal excretion of drugs and metabolites 146
 - Drug interactions due to altered drug excretion 148

11 Pharmacokinetics 150

- Introduction: definition and uses of pharmacokinetics 150
 - Uses of pharmacokinetics 151
 - Scope of this chapter 151
- Drug elimination expressed as clearance 151
- Single-compartment model 153
 - Repeated dosing 154
 - Effect of variation in rate of absorption 154
- More complicated kinetic models 155
 - Two-compartment model 156
 - Saturation kinetics 157
- Population pharmacokinetics 157
- Limitations of pharmacokinetics 158

12 Individual variation, pharmacogenomics and personalised medicine 160

- Introduction 160
- Epidemiological factors and inter-individual variation of drug response 161
 - Ethnicity 161
 - Age 161
 - Pregnancy 162
 - Disease 162
 - Drug interactions 163
- Genetic variation in drug responsiveness 164
 - Single-gene pharmacokinetic disorders 165
- Therapeutic drugs and clinically available pharmacogenomic tests 166
 - Incorporating pharmacogenetic data into daily clinical workflows 167
- Conclusions 168

SECTION 2 Chemical mediators

13 Chemical mediators and the autonomic nervous system 170

Historical aspects 170

The autonomic nervous system 171

Basic anatomy and physiology 171

Transmitters in the autonomic nervous system 174

Some general principles of chemical transmission 174

Presynaptic modulation 174

Postsynaptic modulation 176

Transmitters other than acetylcholine and noradrenaline 177

Co-transmission 177

Termination of transmitter action 177

Denervation supersensitivity 179

Basic steps in neurochemical transmission: sites of drug action 180

14 Cholinergic transmission 182

Muscarinic and nicotinic actions of acetylcholine 182

Acetylcholine receptors 182

Nicotinic receptors 182

Muscarinic receptors 183

Physiology of cholinergic transmission 185

Acetylcholine synthesis and release 185

Electrical events in transmission at fast cholinergic synapses 186

Effects of drugs on cholinergic transmission 188

Drugs affecting muscarinic receptors 189

Drugs affecting autonomic ganglia 192

Drugs that act presynaptically 198

Drugs that enhance cholinergic transmission 198

Other drugs that enhance cholinergic transmission 203

15 Noradrenergic transmission 205

Catecholamines 205

Classification of adrenoceptors 205

Physiology of noradrenergic transmission 208

The noradrenergic neuron 208

Uptake and degradation of catecholamines 210

Drugs acting on noradrenergic transmission 210

Drugs acting on adrenoceptors 211

Drugs that affect noradrenergic neurons 221

16 5-Hydroxytryptamine and the purines 225

5-Hydroxytryptamine 225

Distribution, biosynthesis and degradation 225

Pharmacological effects 228

Drugs acting at 5-HT receptors 229

Clinical conditions in which 5-HT plays a role 231

Serotonin and carcinoid syndrome 231

Pulmonary hypertension 231

Purines 231

Purinerger receptors 232

The purinergic system in health and disease 234

The cardiovascular system 234

Asthma and inflammation 234

Platelets 235

Purines as neurotransmitters 235

Summary 235

17 Local hormones: histamine, lipids, peptides and proteins 237

Introduction 237

What is a 'mediator'? 237

Histamine 238

Synthesis and storage of histamine 238

Histamine release 238

Histamine receptors 238

Histamine actions 238

Eicosanoids 240

General remarks 240

Structure and biosynthesis 240

Prostanoids 242

Leukotrienes 245

Leukotriene receptors 245

Leukotriene actions 246

Other important fatty acid derivatives 247

Platelet-activating factor 248

Biosynthesis 248

Actions and role in inflammation 248

Sphingosine 1-phosphate 248

Biosynthesis and metabolism 248

Receptors and actions 249

Protein and peptide mediators 250

General principles 250

Types of protein and peptide mediator 250

Biosynthesis and regulation of peptides 250

Peptide precursors 251

Diversity within peptide families 252

Peptide trafficking and secretion 252

Bradykinin 252

Source and formation of bradykinin 252

Metabolism and inactivation of bradykinin 253

Bradykinin receptors 253

Actions and role in inflammation 253

Neuropeptides 254

Cytokines 254

Interleukins and related compounds 255

Chemokines 255

Interferons 257

The 'cytokine storm' 257

Proteins and peptides that down-regulate inflammation 257

Concluding remarks 258

18 Cannabinoids 260

Plant-derived cannabinoids ('phytocannabinoids') and their pharmacological effects 260

Pharmacological effects 260

Pharmacokinetic aspects 261

Adverse effects 261

Tolerance and dependence 261

Cannabinoid receptors 261

Endocannabinoids 263

Biosynthesis of endocannabinoids 263

Termination of the endocannabinoid signal 263
Physiological mechanisms 264
Pathological involvement 264
Synthetic cannabinoids 265
Clinical applications 265

19 Nitric oxide and related mediators 267

Introduction 267
Biosynthesis of nitric oxide and its control 267
Degradation and carriage of nitric oxide 269
Effects of nitric oxide 270
 Biochemical and cellular aspects 270
 Vascular effects 271
 Neuronal effects 271
 Host defence 271
Therapeutic aspects 271
 Nitric oxide 271
 Nitric oxide donors/precursors 271
 Inhibition of nitric oxide synthesis 272
 Nitric oxide replacement or potentiation 272
Clinical conditions in which nitric oxide may play a part 272
Related mediators 273

SECTION 3 Drugs affecting major organ systems

20 The heart 275

Introduction 275
Physiology of cardiac function 275
 Cardiac rate and rhythm 275
 Cardiac contraction 279
 Myocardial oxygen consumption and coronary blood flow 280
Autonomic control of the heart 281
 Sympathetic system 281
 Parasympathetic system 282
Cardiac natriuretic peptides 283
Ischaemic heart disease 283
 Angina 283
 Acute coronary syndrome 283
Drugs that affect cardiac function 284
 Antidysrhythmic drugs 284
 Drugs that act on myocardial contraction 287
 Anti-anginal drugs 289

21 The vascular system 294

Introduction 294
Vascular structure and function 294
Control of vascular smooth muscle tone 295
 The vascular endothelium 295
 The renin-angiotensin system 298
Vasoactive drugs 299
 Vasoconstrictor drugs 299
 Vasodilator drugs 300
Clinical uses of vasoactive drugs 305
 Systemic hypertension 305
 Heart failure 307
 Vasodilatory shock and hypotensive states 309

Peripheral vascular disease 310
Raynaud's disease 310
Pulmonary hypertension 310

22 Atherosclerosis and lipoprotein metabolism 313

Introduction 313
Atherogenesis 313
Lipoprotein transport 314
 Dyslipidaemia 315
Prevention of atheromatous disease 316
Lipid-lowering drugs 316
 Statins: HMG-CoA reductase inhibitors 317
 Bempedoic acid 318
 Inhibition of PCSK9 318
 Fibrates 319
 Drugs that inhibit cholesterol absorption 319
 Microsomal triglyceride transport protein (MTP) inhibitors 320
Antisense oligonucleotides 320

23 Haemostasis and thrombosis 322

Introduction 322
Blood coagulation 322
 Coagulation cascade 322
 Vascular endothelium in haemostasis and thrombosis 324
Drugs that act on the coagulation cascade 325
 Coagulation defects 325
 Thrombosis 326
Platelet adhesion and activation 330
Antiplatelet drugs 332
Fibrinolysis (thrombolysis) 334
 Fibrinolytic drugs 334

24 Haematopoietic system and treatment of anaemia 337

Introduction 337
The haematopoietic system 337
Types of anaemia 339
Haematinic agents 339
 Iron 339
 Folic acid and vitamin B₁₂ 342
Haematopoietic growth factors 343
Haemolytic anaemia 347
 Drugs used to treat haemolytic anaemias 347

25 Anti-inflammatory and immunosuppressant drugs 350

Introduction 350
Cyclo-oxygenase inhibitors 350
 Mechanism of action 351
 Pharmacological actions 352
 Some important NSAIDs and COXIBs 356
Antirheumatoid drugs 359
 Disease-modifying antirheumatic drugs 359
 Immunosuppressant drugs 361
Biologic disease-modifying antirheumatic drugs, anticytokine drugs and other biopharmaceuticals 364
Drugs used in gout 365
Antagonists of histamine 367

Possible future developments in anti-inflammatory therapy 369

26 Skin 371

Introduction 371

Structure of skin 371

Common diseases of the skin 374

Acne 374

Rosacea 374

Baldness and hirsutism 376

Eczema 376

Pruritus 376

Urticaria 376

Psoriasis 377

Warts 377

Other infections 377

Melanoma 377

Drugs acting on skin 377

Formulation 377

Principal drugs used in skin disorders 378

Antimicrobial agents 378

Biopharmaceuticals 378

Glucocorticoids and other anti-inflammatory agents 379

Drugs used to control hair growth 380

Retinoids 380

Vitamin D analogues 381

Agents acting by other mechanisms 381

Concluding remarks 382

27 The eye 384

Introduction 384

Special pharmacokinetic considerations in the eye 384

Autonomic control of the lens and pupil, and related therapeutic drugs 385

Treatment of inflammation and infection in the eye 386

Control of intraocular pressure and treatment of glaucoma 387

Prostaglandin FP receptor agonists 387

β_1 adrenoceptor antagonists 387

α_2 adrenoceptor agonists 387

Carbonic anhydrase inhibitors 387

Inhibitors of rho kinase 388

Muscarinic agonists 388

Ocular vasculature and vascular endothelial growth factor inhibitors 388

28 Respiratory system 390

The physiology of respiration 390

Control of breathing 390

Regulation of musculature, blood vessels and glands of the airways 390

Pulmonary disease and its treatment 391

Bronchial asthma 391

Drugs used to treat and prevent asthma 393

Severe acute asthma (status asthmaticus) 398

Allergic emergencies 398

Chronic obstructive pulmonary disease 398

Bronchiectasis 399

Idiopathic pulmonary fibrosis 399

Surfactants 400

Cough 400

29 The kidney and urinary system 402

Introduction 402

Outline of renal function 402

The structure and function of the nephron 402

Tubular function 404

Acid-base balance 407

Potassium balance 408

Excretion of organic molecules 408

Natriuretic peptides 408

Prostaglandins and renal function 409

Drugs acting on the kidney 409

Diuretics 409

Drugs that alter the pH of the urine 413

Drugs that alter the excretion of organic molecules 413

Drugs used in renal failure 414

Hyperphosphataemia 414

Hyperkalaemia 414

Drugs used in urinary tract disorders 414

30 The gastrointestinal tract 416

The innervation and hormones of the gastrointestinal tract 416

Neuronal control 416

Hormonal control 416

Gastric secretion 416

The regulation of acid secretion by parietal cells 416

The coordination of factors regulating acid secretion 418

Drugs used to inhibit or neutralise gastric acid secretion 418

Treatment of *Helicobacter pylori* infection 420

Drugs that protect the mucosa 421

Vomiting 421

The reflex mechanism of vomiting 421

Antiemetic drugs 423

The motility of the GI tract 424

Purgatives 425

Drugs that increase gastrointestinal motility 425

Antidiarrhoeal agents 426

Drugs for chronic bowel disease 427

Drugs affecting the biliary system 428

Future directions 428

31 The control of blood glucose and drug treatment of diabetes mellitus 429

Introduction 429

Control of blood glucose 429

Pancreatic islet hormones 430

Insulin 431

Glucagon 433

Somatostatin 434

Amylin (islet amyloid polypeptide) 434

Incretins 434

Diabetes mellitus 434

Drugs used in the treatment of diabetes 435

Treatment of diabetes mellitus 440

32 Obesity 443

Introduction 443

Definition of obesity 443

Obesity as a health problem 443

Homeostatic mechanisms controlling energy balance 444

The role of peripheral signalling in body weight regulation 444

Neurological circuits that control body weight and eating behaviour 445

The pathophysiology of human obesity 447

Food intake and obesity 448

Physical exercise and obesity 448

Genetic factors and obesity 448

Pharmacological approaches to the problem of obesity 449

Centrally acting appetite suppressants 449

Orlistat 450

GLP-1 receptor agonists 450

New approaches to obesity therapy 451

33 The pituitary and the adrenal cortex 452

The pituitary gland 452

The anterior pituitary gland 452

Hypothalamic hormones 453

Anterior pituitary hormones 454

Posterior pituitary gland 457

The adrenal cortex 458

Glucocorticoids 459

Mineralocorticoids 466

New directions in glucocorticoid therapy 466

34 The thyroid 469

Synthesis, storage and secretion of thyroid hormones 469

Uptake of plasma iodide by the follicle cells 469

Oxidation of iodide and iodination of tyrosine residues 469

Secretion of thyroid hormone 469

Regulation of thyroid function 469

Actions of the thyroid hormones 471

Effects on metabolism 471

Effects on growth and development 471

Mechanism of action 471

Transport and metabolism of thyroid hormones 472

Abnormalities of thyroid function 472

Hyperthyroidism (thyrotoxicosis) 472

Simple, non-toxic goitre 473

Hypothyroidism 473

Drugs used in diseases of the thyroid 473

Hyperthyroidism 473

Hypothyroidism 474

35 The reproductive system 476

Introduction 476

Endocrine control of reproduction 476

Neurohormonal control of the female reproductive system 476

Neurohormonal control of the male reproductive system 478

Behavioural effects of sex hormones 478

Drugs affecting reproductive function 478

Oestrogens 478

Progestogens 481

Postmenopausal hormone replacement therapy (HRT) 481

Androgens 482

Anabolic steroids 483

Anti-androgens 483

Gonadotrophin-releasing hormone (GnRH): agonists and antagonists 483

Gonadotrophins and analogues 484

Drugs used for contraception 485

Oral contraceptives 485

Other drug regimens used for contraception 486

The uterus 486

The motility of the uterus 486

Drugs that stimulate the uterus 486

Drugs that inhibit uterine contraction 488

Erectile dysfunction 488

36 Bone metabolism 491

Introduction 491

Bone structure and composition 491

Bone remodelling 491

The action of cells and cytokines 493

The turnover of bone minerals 493

Hormones involved in bone metabolism and remodelling 493

Disorders of bone 496

Drugs used in bone disorders 496

Bisphosphonates 496

Oestrogens and related compounds 497

Parathyroid hormone and analogues 498

Vitamin D preparations 498

Biopharmaceuticals 498

Calcitonin 499

Calcium salts 499

Calcimimetic compounds 499

SECTION 4 Nervous system

37 Chemical transmission and drug action in the central nervous system 501

Introduction 501

Chemical signalling in the nervous system 501

Targets for drug action 504

Drug action in the central nervous system 504

Blood-brain barrier 506

The classification of psychotropic drugs 507

38 Amino acid transmitters 509

Excitatory amino acids 509

Excitatory amino acids as CNS transmitters 509

Metabolism and release of excitatory amino acids 509

Glutamate 510

Glutamate receptor subtypes 510
Synaptic plasticity and long-term potentiation 512
Drugs acting on glutamate receptors 515

γ -aminobutyric acid 518

Synthesis, storage and function 518
GABA receptors: structure and pharmacology 518
Drugs acting on GABA receptors 519

Glycine 520

Concluding remarks 522

39 Other transmitters and modulators 524

Introduction 524

Noradrenaline 524

Noradrenergic pathways in the CNS 524
Functional aspects 524

Dopamine 526

Dopaminergic pathways in the CNS 526
Dopamine receptors 527
Functional aspects 527

5-Hydroxytryptamine 529

5-HT pathways in the CNS 529
5-HT receptors in the CNS 529
Functional aspects 530
Clinically used drugs 531

Acetylcholine 531

Cholinergic pathways in the CNS 531
Acetylcholine receptors 531
Functional aspects 532

Purines 533

Histamine 534

Other CNS mediators 534

Melatonin 534
Nitric oxide 535
Lipid mediators 535

A final message 537

40 Neurodegenerative diseases 539

Protein misfolding and aggregation in chronic neurodegenerative diseases 539

Mechanisms of neuronal death 540

Excitotoxicity 541
Apoptosis 541
Oxidative stress 543

Ischaemic brain damage 543

Pathophysiology 544
Therapeutic approaches 544

Dementia 544

Pathogenesis of Alzheimer's disease 545
Pathogenesis of dementia with Lewy bodies 546
Therapeutic approaches to dementia 547

Parkinson's disease 548

Features of Parkinson's disease 548
Pathogenesis of Parkinson's disease 549
Drug treatment of Parkinson's disease 550

Essential tremor 553

Huntington's disease 554

Amyotrophic lateral sclerosis 554

Spinal muscular atrophy 554

Multiple sclerosis 554

41 General anaesthetic agents 557

Introduction 557

Mechanism of action of anaesthetic drugs 557

Lipid solubility 557
Effects on ion channels 558
Effects on the nervous system 559
Effects on the cardiovascular and respiratory systems 559

Intravenous anaesthetic agents 560

Propofol 560
Thiopental 560
Etomidate 561
Other intravenous agents 562

Inhalation anaesthetics 563

Pharmacokinetic aspects 563

Individual inhalation anaesthetics 565

Isoflurane, desflurane, sevoflurane, enflurane and halothane 566
Nitrous oxide 566

Sedation and balanced anaesthesia 567

42 Headache 568

Headache 568

Types of headaches 568

Migraine 568
Tension-type headaches 570
Trigeminal autonomic cephalalgias 571
Miscellaneous primary headaches 571

Drug therapy for headache 571

Drugs acting on the 5-HT system 571
Drugs acting on the CGRP system 572
Anti-inflammatory drugs 573
Centrally acting drugs 573
Cardiovascular drugs 573
Miscellaneous group 574
Other non-pharmacological treatments 574

Summary 574

43 Analgesic drugs 575

Introduction 575

Neural mechanisms of pain 575

Modulation in the nociceptive pathway 576
Chemical signalling in the nociceptive pathway 579

Analgesic drugs 581

Opioid drugs 581
Paracetamol 590

Chronic pain 591

Treatment of chronic secondary pain 591
Treatment of chronic primary pain 592
Other drugs used to treat pain 592

44 Local anaesthetics and other drugs affecting sodium channels 595

Local anaesthetics 595

- History 595
- Chemical aspects 595
- Mechanism of action 595
- Unwanted effects 596
- Pharmacokinetic aspects 598
- New approaches 598
- Other drugs that affect sodium channels 601**
 - Tetrodotoxin and saxitoxin 601
 - Agents that affect sodium-channel gating 601

45 Anxiolytic and hypnotic drugs 602

- The nature of anxiety and its treatment 602
- Measurement of anxiolytic activity 603
 - Animal models of anxiety 603
 - Quantifying anxiety in humans 603
- Drugs used to treat anxiety 603
- Delayed anxiolytic effect of drugs acting via serotonergic mechanisms 606
 - Benzodiazepines and related drugs 606
 - Gabapentinoids 610
 - Other potential anxiolytic drugs 610
- Drugs used to treat insomnia (hypnotic drugs) 611
 - Induction of sleep by benzodiazepines 611

46 Antiepileptic drugs 613

- Introduction 613
- The nature of epilepsy 613
 - Types of epilepsy 613
 - Neural mechanisms and animal models of epilepsy 615
- Antiepileptic drugs 616**
 - Carbamazepine 620
 - Phenytoin 620
 - Valproate 621
 - Ethosuximide 622
 - Phenobarbital 622
 - Benzodiazepines 622
 - Newer antiepileptic drugs 622
 - New drugs 624
 - Other uses of antiepileptic drugs 624
 - Antiepileptic drugs and pregnancy 624
- Muscle spasm and muscle relaxants 624

47 Antipsychotic drugs 626

- Introduction 626
- The nature of schizophrenia 626
 - Aetiology and pathogenesis of schizophrenia 627
- Antipsychotic drugs 629**
 - Classification of antipsychotic drugs 629
 - Clinical efficacy in treatment of schizophrenia 630
 - Other uses of antipsychotic drugs 630
 - Pharmacological properties 631
 - Unwanted effects 635
 - Pharmacokinetic aspects 637
- Future developments 638

48 Antidepressant drugs 640

- The nature of depression 640
- Theories of depression 640
 - The monoamine theory 641

- Neuroendocrine mechanisms 642
- Neurotrophic effects and neuroplasticity 642
- Neuropsychological hypothesis 643

Antidepressant drugs 643

- Types of antidepressant drug 643
- Testing of antidepressant drugs 645
- Mechanism of action of conventional antidepressant drugs 649
 - Monoamine uptake inhibitors 652
 - Receptor blocking antidepressants 655
 - Monoamine oxidase inhibitors 656
 - Melatonin agonist 657
 - Rapid-acting antidepressants 657
 - Other antidepressant approaches 658
- Clinical effectiveness of antidepressant treatments 658
- Future antidepressant drugs 659
- Brain stimulation therapies 659
- Drug treatment of bipolar disorder 659**
 - Lithium 660
 - Antiepileptic drugs 661
 - Second-generation antipsychotic drugs 661

49 Psychoactive drugs 663

- Introduction 663
- Psychomotor stimulants 663**
 - Amphetamines 663
 - Methylphenidate 666
 - Modafinil 666
 - Cocaine 666
 - MDMA 667
 - Cathinones 668
 - Methylxanthines 668
 - Nicotine 669
 - Pharmacological effects of nicotine 670
 - Pharmacokinetic aspects 671
 - Addiction and tolerance 671
 - Harmful effects of tobacco smoking 672
 - Other effects of tobacco smoking 673
- Cognition-enhancing drugs 673**
- Psychedelic drugs 674**
 - Lysergic acid diethylamide, psilocybin and mescaline 674
 - Other psychedelic drugs 675
- Dissociative drugs 675**
- Depressants 676**
 - Ethanol 676
 - Pharmacological effects of ethanol 676
 - Pharmacokinetic aspects 679
 - Tolerance and physical dependence 681
- Synthetic cannabinoid receptor agonists 681**

50 Drug use and addiction 683

- Drug use 683**
 - Drug administration 683
 - Drug harm 684
 - Drug addiction 684
 - Tolerance 687
 - Pharmacological approaches to treating drug addiction 688
- Harm reduction 688**



SECTION 5 Drugs used for the treatment of infections and cancer

51 Basic principles of antimicrobial chemotherapy 690

Background 690

The molecular basis of chemotherapy 690

Bacteria 690

Biochemical reactions as potential targets 691

The formed structures of the cell as potential targets 696

Resistance to antibacterial drugs 697

The spread of antibiotic resistance 698

Biochemical mechanisms of resistance to antibiotics 700

Current status of antibiotic resistance in bacteria 701

Resistance to other antimicrobials 702

52 Antibacterial drugs 704

Introduction 704

Gram staining and its significance for drug action 704

Antibacterial agents that interfere with folate synthesis or action 704

Sulfonamides 704

Trimethoprim 706

β -lactam antibiotics and other agents that interfere with bacterial wall or membrane synthesis 707

Penicillins 707

Cephalosporins and cephamycins 709

Other β -lactam antibiotics 710

Other antibiotics that inhibit bacterial cell wall peptidoglycan synthesis 710

Antimicrobial agents affecting bacterial protein synthesis 711

Tetracyclines 711

Aminoglycosides 713

Macrolides 713

Oxazolidinones 714

Fusidic acid 714

Streptogramins 714

Clindamycin 714

Antimicrobial agents affecting topoisomerase 715

Quinolones 715

Miscellaneous antibacterial agents 716

Antimycobacterial agents 716

Drugs used to treat tuberculosis 716

Drugs used to treat leprosy 718

Prospects for new antibacterial drugs 719

53 Antiviral drugs 721

Background information about viruses 721

An outline of virus structure 721

The lifecycle of viruses 721

Mechanisms of viral replication 722

The host-virus interaction 723

Host defences against viruses 723

Viral ploys to circumvent host defences 724

HIV and AIDS 725

Induction of the disease 725

Progress of infection 725

COVID-19 728

Antiviral drugs 729

DNA polymerase inhibitors 729

Reverse transcriptase inhibitors 730

Non-nucleoside reverse transcriptase inhibitors 731

Protease inhibitors 731

Neuraminidase inhibitors and inhibitors of viral coat disassembly 732

Drugs acting through other mechanisms 732

Biopharmaceutical antiviral drugs 732

Other agents 733

Combination therapy for HIV 733

COVID-19 pharmacotherapy 734

Prospects for new antiviral drugs 735

54 Antifungal drugs 736

Fungi and fungal infections 736

Drugs used to treat fungal infections 737

Antifungal antibiotics 737

Synthetic antifungal drugs 739

Future developments 740

55 Antiprotozoal drugs 742

Background 742

Host-parasite interactions 742

Malaria and antimalarial drugs 742

The life cycle of the malaria parasite 744

Antimalarial drugs 745

Potential new antimalarial drugs 751

Amoebiasis and amoebicidal drugs 752

Trypanosomiasis and trypanocidal drugs 753

Other protozoal infections and drugs used to treat them 754

Leishmaniasis 754

Trichomoniasis 754

Giardiasis 755

Toxoplasmosis 755

Pneumocystis 755

Future developments 755

56 Anthelmintic drugs 757

Helminth infections 757

Anthelmintic drugs 758

Benzimidazoles 760

Praziquantel 761

Piperazine 761

Diethylcarbamazine 761

Niclosamide 761

Levamisole 762

Ivermectin 762

Resistance to anthelmintic drugs 762

Vaccines and other novel approaches 763

57 Anticancer drugs 764

Introduction 764

The pathogenesis of cancer 764

- The genesis of a cancer cell 765
- The special characteristics of cancer cells 765
- General principles of cytotoxic anticancer drugs 767**
- Anticancer drugs 768**
 - Alkylating agents and related compounds 771
 - Antimetabolites 773
 - Cytotoxic antibiotics 774
 - Plant derivatives 775
 - Hormones 776
 - Hormone antagonists 776
 - Monoclonal antibodies 777
 - Protein kinase inhibitors 778
 - Miscellaneous agents 779
 - Resistance to anticancer drugs 780
 - Combination therapies 780
 - Control of emesis and myelosuppression 781
- Future developments 781**

SECTION 6 Special topics

58 Harmful effects of drugs 783

- Introduction 783**
- Classification of adverse drug reactions 783**
 - Adverse effects related to the known pharmacological action of the drug 784
 - Adverse effects unrelated to the known pharmacological action of the drug 784
- Drug toxicity 784**
 - Toxicity testing 784
 - General mechanisms of toxin-induced cell damage and cell death 785
 - Mutagenesis and assessment of genotoxic potential 787

- Immunological reactions to drugs 791**
 - Immunological mechanisms 791
 - Clinical types of allergic response to drugs 791

59 Lifestyle and drugs in sport 794

- What are lifestyle drugs? 794**
- Classification of lifestyle drugs 794**
- Cognitive enhancers 795**
- Drugs and sex 796**
- Drugs in sport 797**
 - Anabolic steroids and related compounds 798
 - Drugs that increase oxygen delivery to muscles 799
- Regulatory, societal and ethical issues 800**
- Conclusion 801**

60 Drug discovery and development 802

- Drug discovery: background 802**
- The stages of a project 803**
 - The drug discovery phase 804
 - Preclinical development 806
 - Clinical development 807
- Biopharmaceuticals 808**
- Commercial aspects 808**
 - Drug repurposing 809
 - Generic drugs 809
- Future prospects 809**
- A final word 811**

Index 812

Self-assessment questions compiled by Dr. Christine Edmead, University of Bath, are available through eBooks.Health. Elsevier.com

Video and Case Study Contents

 Online content accessible via <https://ebooks.health.elsevier.com> using the pin in the front of the book.

VIDEOS

In conversation with Humphrey Rang

Interview with Humphrey Rang of *Rang & Dale's Pharmacology* textbook. In discussion with David MacEwan, Humphrey recalls the history and development of the textbook and reflects on his distinguished career.

In conversation with Jim Ritter

Interview with Jim Ritter, author of *Rang & Dale's Pharmacology* textbook. In discussion with David MacEwan, Jim reflects on how the textbook has developed during his time as one of the longest-serving authors.

In conversation with Rod Flower

Interview with Rod Flower, one of the earliest authors of *Rang & Dale's Pharmacology* textbook. In conversation, Rod reflects on changes during his time working on the popular textbook.

In conversation with Graeme Henderson

Interview with Graeme Henderson, author of *Rang & Dale's Pharmacology* textbook. Here, Graeme reflects on how the textbook has developed during his time as its Editor and how *Rang & Dale's Pharmacology* has impacted the teaching of pharmacology and drug use over the years.

In conversation with Yoon Loke

Interview with Yoon Loke, author of *Rang & Dale's Pharmacology* textbook. In dialogue with David MacEwan, Yoon discusses his experiences co-authoring the successful textbook and how it has influenced teaching of pharmacology to medical students.

In conversation with Emma Robinson

Interview with Emma Robinson, one of the most recent co-authors of *Rang & Dale's Pharmacology* textbook. In discussion, Emma discusses her early impressions as co-author of the successful book, and how she tries to incorporate her own teaching method into the textbook.

In conversation with James Fullerton

Interview with James Fullerton, co-author of *Rang & Dale's Pharmacology* textbook. In discussion with David MacEwan, James discusses his impressions of the textbook and how it influences how medical school students learn about drugs, applying that knowledge in the clinic.

Pharmacology in practice: clinical overdose

Topic video with Adam Danashmend, clinical registrar in London. Adam gives his advice on the importance of pharmacology to doctors, and opioid overdose cases in the clinic.

Pharmacology in practice: role of pharmacology in undergraduate medical education

Dr Mohammad Sarwar describes the clinical use of anaesthetics and pain relief in preoperative, operative and postoperative

clinical settings, to inform students of the most appropriate drug combinations used by anaesthesiologists.

Pharmacology in practice: importance of chemistry, drug-receptor interactions and pharmacokinetics to people who use opioids

Rang & Dale author Graeme Henderson describes opioid use and misuse, outlining how agonists and antagonists are used on the street and the pharmacological knowledge underlying their use.

Pharmacology in practice: investigation of the frequency of narcotic misuse

Pharmacology graduate Meurig Shotton describes his project analysing the purity of narcotics and use of cutting-agents in social nonclinical settings, such as music festivals.

Topic: what are drugs and how do they work? Understanding receptor theory better

Rang & Dale author David MacEwan describes drugs, receptors and receptor theory in more depth to help students understand these pharmacology basics.

Topic: enzyme inducers and inhibitor – the logical approach

Rang & Dale author Yoon Loke describes how enzyme inducers and inhibitors have the ability to modify the actions of other drugs taken concurrently.

CASE STUDIES

Inflammation case study

(Chapters 7 and 25)

Cardiovascular case study

(Chapters 20–23)

Respiratory case study

(Chapter 28)

Food and glucose regulation case study

(Chapters 31 and 32)

Neurodegenerative disease case study

(Chapter 40)

Epilepsy case study

(Chapter 46)

Cancer case study

(Chapter 57)